Skip to Main Content

Amid rising concern over a lack of antibiotics, a new analysis finds most drug makers are failing to expand their pipelines to sufficiently combat resistance, although more companies are sharing surveillance data on where resistance is occurring and are no longer overselling the medicines.

Overall, the number of antibiotics being developed has increased only marginally in the past two years and just nine of these medicines are considered novel, most of which are being pursued by small and medium-sized companies with fewer resources than global drug makers. And while more clinical-stage antibiotics are supported by plans to ensure better access, most efforts remain patchy.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!